InflaRx N.V. (IFRX) Regains Compliance With Nasdaq

InflaRx N.V. (NASDAQ:IFRX) is one of the top 10 hot penny stocks to buy now. InflaRx N.V. (NASDAQ:IFRX) announced on April 28 that it received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC on April 27, informing management that the company regained compliance with Nasdaq’s minimum bid price requirement set forth under Nasdaq Listing Rule 5450(a)(1). The notice stated that InflaRx N.V. (NASDAQ:IFRX) regained compliance with the Minimum Bid Price Requirement because the closing bid price of its ordinary shares has been $1.00 per share or greater for 10 consecutive business days, from April 13, 2026, to April 24, 2026, adding that the matter is now closed.

Is InflaRx (IFRX) the Best German Stock to Buy According to Hedge Funds?

In a separate development, Oppenheimer assumed coverage of InflaRx N.V. (NASDAQ:IFRX) with an Outperform rating on April 24, bringing the price target on the stock to $5 from $7 and stating that it considers izicopan to be the company’s main value driver. Izicopan is an oral C5aR inhibitor with a differentiated pharmacological profile vs. avacopan.

InflaRx N.V. (NASDAQ:IFRX) is a clinical-stage biopharmaceutical company involved in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. The company’s primary product candidate is Vilobelimab.

While we acknowledge the risk and potential of IFRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than IFRX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.